Comparative Left Ventricular Functional and Neurohumoral Effects of Chronic Treatment With Carvedilol Versus Metoprolol in Patients With Dilated Cardiomyopathy
Open Access
- 1 January 2001
- journal article
- clinical trial
- Published by Japanese Circulation Society in Japanese Circulation Journal
- Vol. 65 (11) , 931-936
- https://doi.org/10.1253/jcj.65.931
Abstract
The efficacy of treating dilated cardiomyopathy with metoprolol was compared with that of carvedilol. Metoprolol was administered to 29 patients, and carvedilol to 62. Patients who could not be dosed with up to 40 mg daily of metoprolol or 20 mg daily of carvedilol were defined as intolerant. As well as the tolerability of these β-blockers, the effects on left ventricular end-diastolic dimension (LVDd), fractional shortening (FS), plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) concentrations, the delayed heart and mediastinum (H/M) ratio determined from metaiodobenzylguanidine imaging were compared. Drug intolerance occurred in 24% of patients in the metoprolol group and 19% in the carvedilol group. Among the drug-tolerant patients, LVDd, FS and plasma BNP concentration improved in both groups and to the same degree. Only 25% of drug-tolerant patients in the metoprolol group had a delayed H/M ratio below 1.9 compared with 57% in the carvedilol group. Both metoprolol and carvedilol, when tolerated, improve cardiac function and neurohumoral factors to the same degree. However, carvedilol is preferable to metoprolol for patients with a low delayed H/M ratio. (Jpn Circ J 2001; 65: 931 - 936)Keywords
This publication has 25 references indexed in Scilit:
- Beta-blockade in heart failure: A comparison of carvedilol with metoprololJournal of the American College of Cardiology, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- The role of third-generation beta-blocking agents in chronic heart failureClinical Cardiology, 1998
- Ejection Fraction Improvement by ??-Blocker Treatment in Patients with Heart FailureJournal of Cardiovascular Pharmacology, 1998
- Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overloadJournal of the American College of Cardiology, 1996
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptorNature, 1995
- Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy.Circulation, 1994
- SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidantEuropean Journal of Pharmacology, 1994
- Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathyJournal of the American College of Cardiology, 1988